Shuai Yuan, Michael G Clark, Gabrielle Shakt, Michael G Levin, Katherine Hartmann, Renae Judy, Tia Dinatale, Amy Voorhees, Julie A Lynch, Saiju Pyarajan, Daniel Levy, Roby Joehanes, Kyong-Mi Chang, Jennifer A Brody, Joshua C Bis, Bruce M Psaty, Benjamin F Voight, Philip S Tsao, Gregory T Jones, Scott M Damrauer
{"title":"Epigenome-Wide Association Study of Abdominal Aortic Aneurysm Identifies Central Role for Inflammatory Pathways.","authors":"Shuai Yuan, Michael G Clark, Gabrielle Shakt, Michael G Levin, Katherine Hartmann, Renae Judy, Tia Dinatale, Amy Voorhees, Julie A Lynch, Saiju Pyarajan, Daniel Levy, Roby Joehanes, Kyong-Mi Chang, Jennifer A Brody, Joshua C Bis, Bruce M Psaty, Benjamin F Voight, Philip S Tsao, Gregory T Jones, Scott M Damrauer","doi":"10.1161/CIRCULATIONAHA.126.079863","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Epigenetic mechanisms underlying susceptibility to abdominal aortic aneurysm (AAA) remain poorly understood. Identifying causal DNA methylation markers for AAA can elucidate the regulatory processes that drive aneurysm formation and accelerate translational applications. We leveraged the Veterans Affairs (VA) Million Veteran Program to identify methylation biomarkers and delineate underlying pathways.</p><p><strong>Methods: </strong>We first conducted an epigenome-wide association study of incident AAA (1324 cases and 42 065 noncases), performed stratified analyses by population group and smoking status, and conducted Mendelian randomization to facilitate causal inference of the CpG-AAA association. Chromatin state, island context, and transcription factor binding were implicated through functional annotation of identified CpGs. To identify genes impacted by change in methylation state, we aligned associations with transcriptional data obtained in blood, aorta, and liver. We performed expression quantitative trait methylation to capture CpG-gene-expression links across the genome. Network Mendelian randomization was used to test cardiometabolic and inflammatory mediation. Finally, we developed a methylation risk score for AAA using penalized regression and evaluated its performance against a clinical model in the Million Veteran Program and 2 external studies.</p><p><strong>Results: </strong>Epigenome-wide association study identified 1253 CpGs associated with incident AAA, and Mendelian randomization supported a putative causal role for 143 of these associations. Functional annotation pointed to predominantly distal, enhancer-centered regulation and enrichment of inflammatory transcription factor programs (eg, activator protein-1 and nuclear factor κB). This distal architecture was consistent with expression quantitative trait methylation results, which showed a larger number of trans associations. Among 143 CpGs associated with AAA in Mendelian randomization analyses, we identified 213 CpG-gene expression pairs with strong colocalization support, including <i>AGER, C2</i>, and <i>DDR1</i>. Multi-trait colocalization further prioritized 8 CpG-gene expression-AAA links with evidence of a shared genetic signal. Network Mendelian randomization identified 135 putative mediation pathways linking CpGs to AAA, including 58 via cardiometabolic traits and 77 via inflammation-related traits. Blood lipid traits mediated >40% of the associations between AAA risk and CpGs near <i>LDLR</i> (cg19305903) and <i>TRIB1</i> (cg14128479). Among inflammation-related mediators, circulating DAG1, NEXN, MMP9, IL1RN, and MMP13 were prioritized as potential intermediates. Additionally, a CpG selection process was used to develop a methylation risk score for AAA, which strongly associated with disease in both the discovery cohort and 2 external validation cohorts, even after adjustment for a full suite of clinical covariates.</p><p><strong>Conclusions: </strong>This study identified putative causal DNA methylation markers for AAA, and multi-omics analyses implicate activator protein-1-linked inflammatory transcriptional programs, blood lipids, and multiple inflammation-related proteins as key pathways underlying methylation-associated AAA risk.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3000,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13629486/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1161/CIRCULATIONAHA.126.079863","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Epigenetic mechanisms underlying susceptibility to abdominal aortic aneurysm (AAA) remain poorly understood. Identifying causal DNA methylation markers for AAA can elucidate the regulatory processes that drive aneurysm formation and accelerate translational applications. We leveraged the Veterans Affairs (VA) Million Veteran Program to identify methylation biomarkers and delineate underlying pathways.
Methods: We first conducted an epigenome-wide association study of incident AAA (1324 cases and 42 065 noncases), performed stratified analyses by population group and smoking status, and conducted Mendelian randomization to facilitate causal inference of the CpG-AAA association. Chromatin state, island context, and transcription factor binding were implicated through functional annotation of identified CpGs. To identify genes impacted by change in methylation state, we aligned associations with transcriptional data obtained in blood, aorta, and liver. We performed expression quantitative trait methylation to capture CpG-gene-expression links across the genome. Network Mendelian randomization was used to test cardiometabolic and inflammatory mediation. Finally, we developed a methylation risk score for AAA using penalized regression and evaluated its performance against a clinical model in the Million Veteran Program and 2 external studies.
Results: Epigenome-wide association study identified 1253 CpGs associated with incident AAA, and Mendelian randomization supported a putative causal role for 143 of these associations. Functional annotation pointed to predominantly distal, enhancer-centered regulation and enrichment of inflammatory transcription factor programs (eg, activator protein-1 and nuclear factor κB). This distal architecture was consistent with expression quantitative trait methylation results, which showed a larger number of trans associations. Among 143 CpGs associated with AAA in Mendelian randomization analyses, we identified 213 CpG-gene expression pairs with strong colocalization support, including AGER, C2, and DDR1. Multi-trait colocalization further prioritized 8 CpG-gene expression-AAA links with evidence of a shared genetic signal. Network Mendelian randomization identified 135 putative mediation pathways linking CpGs to AAA, including 58 via cardiometabolic traits and 77 via inflammation-related traits. Blood lipid traits mediated >40% of the associations between AAA risk and CpGs near LDLR (cg19305903) and TRIB1 (cg14128479). Among inflammation-related mediators, circulating DAG1, NEXN, MMP9, IL1RN, and MMP13 were prioritized as potential intermediates. Additionally, a CpG selection process was used to develop a methylation risk score for AAA, which strongly associated with disease in both the discovery cohort and 2 external validation cohorts, even after adjustment for a full suite of clinical covariates.
Conclusions: This study identified putative causal DNA methylation markers for AAA, and multi-omics analyses implicate activator protein-1-linked inflammatory transcriptional programs, blood lipids, and multiple inflammation-related proteins as key pathways underlying methylation-associated AAA risk.
期刊介绍:
Circulation is a platform that publishes a diverse range of content related to cardiovascular health and disease. This includes original research manuscripts, review articles, and other contributions spanning observational studies, clinical trials, epidemiology, health services, outcomes studies, and advancements in basic and translational research. The journal serves as a vital resource for professionals and researchers in the field of cardiovascular health, providing a comprehensive platform for disseminating knowledge and fostering advancements in the understanding and management of cardiovascular issues.